Arvinas Inc (NASDAQ:ARVN) Receives Consensus Rating of “Buy” from Brokerages

Share on StockTwits

Shares of Arvinas Inc (NASDAQ:ARVN) have been assigned an average recommendation of “Buy” from the thirteen analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $50.00.

A number of brokerages recently commented on ARVN. Wedbush lifted their target price on shares of Arvinas from $39.00 to $60.00 and gave the stock an “outperform” rating in a research report on Friday, January 24th. Cantor Fitzgerald lifted their target price on shares of Arvinas from $42.00 to $75.00 and gave the stock an “overweight” rating in a research report on Friday, December 20th. Zacks Investment Research lowered shares of Arvinas from a “buy” rating to a “hold” rating in a report on Thursday. HC Wainwright started coverage on shares of Arvinas in a report on Thursday, December 19th. They issued a “buy” rating and a $50.00 price target on the stock. Finally, BidaskClub lowered shares of Arvinas from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 1st.

Shares of NASDAQ:ARVN opened at $50.30 on Monday. The stock has a market cap of $1.78 billion, a PE ratio of -24.30 and a beta of 2.69. The company’s fifty day moving average is $48.04 and its 200 day moving average is $32.30. Arvinas has a 52 week low of $14.06 and a 52 week high of $54.95. The company has a quick ratio of 6.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.03.

In other Arvinas news, CFO Sean A. Cassidy sold 10,000 shares of the firm’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $51.02, for a total value of $510,200.00. Following the sale, the chief financial officer now owns 154,517 shares of the company’s stock, valued at approximately $7,883,457.34. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 31.77% of the stock is owned by company insiders.

A number of institutional investors have recently made changes to their positions in ARVN. Canaan Partners IX LLC bought a new stake in Arvinas in the 4th quarter worth $184,476,000. RA Capital Management L.P. boosted its stake in shares of Arvinas by 120.8% during the 4th quarter. RA Capital Management L.P. now owns 3,672,872 shares of the company’s stock valued at $150,918,000 after purchasing an additional 2,009,360 shares in the last quarter. 5AM Venture Management LLC bought a new stake in shares of Arvinas during the 4th quarter valued at about $56,639,000. Perceptive Advisors LLC bought a new stake in shares of Arvinas during the 4th quarter valued at about $16,436,000. Finally, ArrowMark Colorado Holdings LLC boosted its stake in shares of Arvinas by 657.1% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 378,560 shares of the company’s stock valued at $15,555,000 after purchasing an additional 328,560 shares in the last quarter. 61.36% of the stock is currently owned by institutional investors and hedge funds.

Arvinas Company Profile

Arvinas, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer.

Featured Story: Understanding Market Liquidity

Analyst Recommendations for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.